Yuriko Bio publishes its preclinical results for human-sourced antibody nasal sprays to prevent new coronary infections

InvisiMask is a patented human-source monoclonal antibody nasal spray designed to mediat a new coronavirus transmitted by droplets and particles in the air through the nasal cavity, the main entry point of viral infection.
it is known that the antibody binds to the S1 prickly protein of the new coronavirus (SARS-CoV-2) to prevent the virus from binding to the ACE2 subject on the upper respiratory tract cells, thereby preventing the virus from invading the cells and causing infection.
as a human-origin antibody, InvisiMask is expected to reduce the risk of side effects caused by immunogenicity.
possible to cause immunogenic reactions in the human body, usually using antibodies or exogeneted peptide segments from animal sources.
same time, Yuriko Bio used proprietary adhesion technology to engineer this monoclonal antibody to increase the duration of the antibody's stay on the surface of the mucous membranes of the respiratory tract and to extend the protection against infection.
it's worth noting that this antibody nasal spray can be stored and transported at room temperature, helping to simplify distribution requirements and expand the range of use.
the human-sourced antibody, which is highly affinity and specific to S proteins, binds to and suppresses more than 20 variants of the new coronavirus SARSF-CoV-2, including the highly contagious D614G variant, according to a Urico Biosuperials press release.
at a minimum dose of 25 micrograms, antibodies provided at least 10 hours of anti-infection protection for mice exposed to the highest viral load (10E7 virus particles in the nasal cavity).
no adverse reactions were observed in preclinical studies.
photo source: Eurekas Announces Successful Preclinical Therapeutic Results of InvisiMask™ Human Antibody Nasal Spray ST SARS-CoV-2 Infect. Retrieved Dec 14 from Source: Supplied